Notification of Annual General Meeting and Extraordinary General Meeting
...ty's site: http://www.magna.isa.gov.il . ABOUT xtl BIOPHARMACEUTICALS LTD. xtl Biopharmaceuticals Ltd. ("XTL") is engaged in the ...he treatment of diabetic neuropathic pain and HCV. xtl is developing Bicifadine, a serotonin and norepine...XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
...ital well into the first quarter of 2009." ABOUT xtl BIOPHARMACEUTICALS LTD. xtl Biopharmaceuticals Ltd. ("XTL") is engaged in the ...he treatment of diabetic neuropathic pain and HCV. xtl is developing Bicifadine, a serotonin and norepine...XTL Announces Delisting From the Official List of the United Kingdom Listing Authority
...SDAQ, or trade their ordinary shares on the TASE. xtl Biopharmaceuticals Ltd. has further announced that...1-212-815-3004, jpaltrowitz@bankofny.com About xtl Biopharmaceuticals Ltd. xtl Biopharmaceuticals Ltd. ("XTL") is engaged in the ...XTL Provides Update on Phase I Clinical Trial of XTL-2125
... New York, June 06, 2007 /PRNewswire-FirstCall/ -- xtl Biopharmaceuticals Ltd. announced today that it ha...rved in the placebo group. Based on these results, xtl has decided to suspend further development of XTL-...f this Phase I trial concludes our research on the xtl legacy compounds that we inherited. Through an agg...Extraordinary General Meetings Statement -- XTL Also Announces Board and Management Changes
REHOVOT, Israel, March 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) announces the results of its Extraordinary General Meetings ("EGMs") held earlier today. All of the resolutions at the EGMs were passed. The current board of directors consists of Mark...XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
NEW YORK, August 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB ; LSE: XTL; TASE: XTL), a biopharmaceutical company engaged in the acquisition, development and commercialization of therapeutics for the treatment of unmet medical needs, particularly neuropathic pain and...Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
...f all of our stakeholders." Ron Bentsur has more than a decade of experience in the biotech industry. Most recently, Mr. Bentsur served as CEO of xtl Biopharmaceuticals, a position he held from January 2006 until April 2009. Prior to his tenure at XTL, Mr. Bentsur was with the Company from 2000-200...XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
... VALLEY COTTAGE, N.Y., March 11 /PRNewswire-FirstCall/ -- xtl Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) announced today that its Extraordinary General Meetings ("EGMs") were postponed for one week in a...